Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | P2Y12 platelet receptorSmall molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12-30 · NCT06577519 · CT.gov ↗
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
26 June 2026Topline resultSumecigrel (formerly vicagrel)Vcare reports completed Phase III studies of Sumecigrel versus clopidogrel
China · Jiangsu Vcare PharmaTech Co., Ltd. · Source ↗
Q2 2026Filing acceptedSumecigrel (formerly vicagrel)NMPA accepts NDA for Sumecigrel Capsule (formerly vicagrel)
China, NMPA · Jiangsu Vcare PharmaTech Co., Ltd. · Source ↗
Financial reports
No financial reports recorded.